Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis.
Aortic aneurysm
Campylobacter
Microbiota
Oral bacteria
Proton pump inhibitor
Takayasu arteritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
24 03 2023
24 03 2023
Historique:
received:
12
11
2022
accepted:
16
03
2023
medline:
28
3
2023
entrez:
25
3
2023
pubmed:
26
3
2023
Statut:
epublish
Résumé
Takayasu arteritis (TAK) is an autoimmune large vessel vasculitis that affects the aorta and its major branches, eventually leading to the development of aortic aneurysm and vascular stenosis or occlusion. This retrospective and prospective study aimed to investigate whether the gut dysbiosis exists in patients with TAK and to identify specific gut microorganisms related to aortic aneurysm formation/progression in TAK. We analysed the faecal microbiome of 76 patients with TAK and 56 healthy controls (HCs) using 16S ribosomal RNA sequencing. We examined the relationship between the composition of the gut microbiota and clinical parameters. The patients with TAK showed an altered gut microbiota with a higher abundance of oral-derived bacteria, such as Streptococcus and Campylobacter, regardless of the disease activity, than HCs. This increase was significantly associated with the administration of a proton pump inhibitor used for preventing gastric ulcers in patients treated with aspirin and glucocorticoids. Among patients taking a proton pump inhibitor, Campylobacter was more frequently detected in those who underwent vascular surgeries and endovascular therapy for aortic dilatation than in those who did not. Among the genus of Campylobacter, Campylobacter gracilis in the gut microbiome was significantly associated with clinical events related to aortic aneurysm formation/worsening in patients with TAK. In a prospective analysis, patients with a gut microbiome positive for Campylobacter were significantly more likely to require interventions for aortic dilatation than those who were negative for Campylobacter. Furthermore, patients with TAK who were positive for C. gracilis by polymerase chain reaction showed a tendency to have severe aortic aneurysms. A specific increase in oral-derived Campylobacter in the gut may be a novel predictor of aortic aneurysm formation/progression in patients with TAK.
Sections du résumé
BACKGROUND
Takayasu arteritis (TAK) is an autoimmune large vessel vasculitis that affects the aorta and its major branches, eventually leading to the development of aortic aneurysm and vascular stenosis or occlusion. This retrospective and prospective study aimed to investigate whether the gut dysbiosis exists in patients with TAK and to identify specific gut microorganisms related to aortic aneurysm formation/progression in TAK.
METHODS
We analysed the faecal microbiome of 76 patients with TAK and 56 healthy controls (HCs) using 16S ribosomal RNA sequencing. We examined the relationship between the composition of the gut microbiota and clinical parameters.
RESULTS
The patients with TAK showed an altered gut microbiota with a higher abundance of oral-derived bacteria, such as Streptococcus and Campylobacter, regardless of the disease activity, than HCs. This increase was significantly associated with the administration of a proton pump inhibitor used for preventing gastric ulcers in patients treated with aspirin and glucocorticoids. Among patients taking a proton pump inhibitor, Campylobacter was more frequently detected in those who underwent vascular surgeries and endovascular therapy for aortic dilatation than in those who did not. Among the genus of Campylobacter, Campylobacter gracilis in the gut microbiome was significantly associated with clinical events related to aortic aneurysm formation/worsening in patients with TAK. In a prospective analysis, patients with a gut microbiome positive for Campylobacter were significantly more likely to require interventions for aortic dilatation than those who were negative for Campylobacter. Furthermore, patients with TAK who were positive for C. gracilis by polymerase chain reaction showed a tendency to have severe aortic aneurysms.
CONCLUSIONS
A specific increase in oral-derived Campylobacter in the gut may be a novel predictor of aortic aneurysm formation/progression in patients with TAK.
Identifiants
pubmed: 36964623
doi: 10.1186/s13075-023-03031-9
pii: 10.1186/s13075-023-03031-9
pmc: PMC10037851
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Informations de copyright
© 2023. The Author(s).
Références
Arthritis Rheumatol. 2023 Feb;75(2):266-278
pubmed: 36054683
Immunity. 2019 Apr 16;50(4):1007-1023
pubmed: 30995492
Circulation. 2015 Nov 3;132(18):1701-9
pubmed: 26354799
Sci Rep. 2019 Aug 19;9(1):12000
pubmed: 31427714
Ann Intern Med. 1994 Jun 1;120(11):919-29
pubmed: 7909656
BMC Res Notes. 2013 Nov 12;6:455
pubmed: 24215903
Gut. 2016 May;65(5):749-56
pubmed: 26719299
Curr Opin Rheumatol. 2019 Sep;31(5):471-474
pubmed: 31192811
Ann Rheum Dis. 2018 Mar;77(3):348-354
pubmed: 29191819
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Mod Rheumatol. 2019 Mar;29(2):287-293
pubmed: 30427262
BMC Microbiol. 2022 Apr 27;22(1):117
pubmed: 35477382
Circ J. 2010 Jun;74(6):1236-41
pubmed: 20467149
BMC Genomics. 2021 Jul 10;22(1):527
pubmed: 34246242
Pathog Immun. 2019 Mar 15;4(1):105-123
pubmed: 30993253
Mayo Clin Proc. 2013 Aug;88(8):822-30
pubmed: 23849994
Nature. 2016 Jul 06;535(7610):75-84
pubmed: 27383982
Int J Cardiol. 2023 Jan 15;371:418-419
pubmed: 36174823
Circulation. 1999 Jul 6;100(1):55-60
pubmed: 10393681
Ann Rheum Dis. 2020 Feb;79(2):e21
pubmed: 30530823
Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434
pubmed: 31951279
Gut. 2022 Jan;71(1):16-24
pubmed: 34226290
Gut. 2016 May;65(5):740-8
pubmed: 26657899
Ann Rheum Dis. 2021 Jul;80(7):e121
pubmed: 30992294
Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-32-5
pubmed: 25436391
Gut. 2022 Jan;71(1):111-118
pubmed: 34210775
Rheumatology (Oxford). 2006 May;45(5):545-8
pubmed: 16352633
Int J Cardiol. 1996 Aug;54 Suppl:S155-63
pubmed: 9119518
J Vasc Surg. 2006 Nov;44(5):1055-60
pubmed: 17098542
Rheumatology (Oxford). 2022 Apr 11;61(4):1376-1384
pubmed: 34363461
Swiss Med Wkly. 2011 Jan 17;141:w13156
pubmed: 21243547
Stroke. 2022 Mar;53(3):895-903
pubmed: 34727738
Rheumatology (Oxford). 2019 Feb 1;58(2):206-219
pubmed: 29635396
PLoS Comput Biol. 2021 Nov 8;17(11):e1009581
pubmed: 34748542
Ann Rheum Dis. 2020 Jan;79(1):19-30
pubmed: 31270110
Sci Rep. 2021 Mar 15;11(1):5926
pubmed: 33723291
Arthritis Rheum. 2006 Oct;54(10):3306-9
pubmed: 17009265
Int Heart J. 2013;54(6):405-11
pubmed: 24309452
Mayo Clin Proc. 2018 Feb;93(2):240-246
pubmed: 29406201
Am J Med Sci. 2017 Dec;354(6):539-547
pubmed: 29208249
Arthritis Rheumatol. 2021 Aug;73(8):1349-1365
pubmed: 34235884
Arthritis Rheum. 1990 Aug;33(8):1129-34
pubmed: 1975175
Circ J. 2020 Jan 24;84(2):299-359
pubmed: 31956163
J Clin Microbiol. 1985 Nov;22(5):799-802
pubmed: 4056006
Rheumatology (Oxford). 2022 May 30;61(6):2360-2368
pubmed: 34528074
BMJ. 2000 Nov 11;321(7270):1183-7
pubmed: 11073508
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
Ann Rheum Dis. 2009 Mar;68(3):318-23
pubmed: 18413441
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Curr Opin Rheumatol. 2015 Jul;27(4):397-405
pubmed: 26002032
Arthritis Rheumatol. 2015 May;67(5):1353-60
pubmed: 25604824